Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

TD Cowen made a significant adjustment to its stance on Merck (NSE:PROR) shares, downgrading the pharmaceutical giant from "Buy" to "Hold". Accompanying the downgrade, the firm also revised its price ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

What will the company do once it loses patent protection for its crown jewel? Merck's post-Keytruda plans, interestingly enough, include Keytruda. The company is developing a subcutaneous (SC ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC's Squawk on the ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK ...